McArthur, Carole P.Abrantes, Pedro Miguel dos SantosAwasom, CharlesAyuk, L.Africa, Charlene W.J.2014-07-302014-07-302013McArthur, C.P., et al. (2013). Drug susceptibility profiles of Candida species isolated from the oral mucosa of HIV-positive West African patients using the TREK Sensititre system. American Society for Microbiology 113th General Meeting, 199/2335, Denver, Colorado, U.S.A, 18-21 May 2013http://hdl.handle.net/10566/1138www.asm.org/asm2013Poster presented at ASM2013, 113th General Meeting, American Society of Microbiology, 18-21 May, Denver, ColoradoBACKGROUND: Candida infections are a common cause of death in immunocompromised patients. The prevalence and anti-mycotic drug susceptibility profiles of Candida species from Cameroon in Africa are unavailable. This study was prompted by an increasing incidence of treatment failure. Drug susceptibility profiles, necessary to improve treatment outcomes, is particularly important in countries where the sale of antimicrobials and antifungals is uncontrolled and resistance may emerge due to the indiscriminate use. OBJECTIVE: The goal of this study was to characterize and determine drug susceptibility of oral Candida species in Cameroonian patients with HIV/AIDS. MATERIALS AND METHODS: Candida species were isolated from the oral cavity of 126 HIV-positive patients attending a local HIV/AIDS clinic in the Cameroon. Drug susceptibility to azoles and echinocandins was determined using the commercial TREK Sensititre® YeastOne™ platform that provides the minimal inhibitory concentration of amphotericin B, 5-flucytosine, anidulafungin, caspofungin, micafungin, fluconazole, itraconazole, posaconazole, and voriconazole. RESULTS: Ninety two isolates identified were Candida albicans. Remaining isolates were C. glabrata (24), C. tropicalis (4), C. krusei (3), C. parapsilopsis/lusitanreae/keyfr (2), and one isolate was C. dubliniensis. More than 50% of C. albicans isolated were resistant to azoles but 115 Candida species (87%) were susceptible to amphotericin B. Twenty one of the twenty four C.glabrata identified (88%) were resistant to micafungin. The majority of Cameroonian Candida species were sensitive to flucytosine (5-FC) (95%) and echinocandins (79%). CONCLUSIONS: The report of azole resistance in all Candida species isolated from immunocompromised patients in Cameroon is a new and important observation. We found the approach using a broad screening platform an effective means to obtain data rapidly. We propose confirmation of these data and regional surveillance of Candida species in other areas in Cameroon and surrounding countries to develop an effective public health management and treatment strategy.enThis file may be freely used for educational uses, as long as it is not altered in any way. No commercial reproduction or distribution of this file is permitted without written permission of the authors.Candidaazolesechinocandinsantifungal drugsdrug resistanceTREKPoster